drugset / Trial / NCT05427630
Dose-Ranging Trial of Inhaled Cannabis for Acute Migraine Treatment
RandomizedCrossoverQuadruple-blindTreatment
Summary
This pilot crossover study will evaluate 3 different potencies of inhaled cannabis (2.5%, 5%, and 10%) and inhaled placebo cannabis for the acute treatment of migraine.
Timeline
- Start
- 2023-02-15
- Primary completion
- 2027-12-01
- Completion
- 2027-12-01
Outcome
Outcome not reported
Stopped (Business): “Inadequate funding”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | THC | Unknown | 2.5 % | Inhaled |
| Subject | THC | Unknown | 5 % | Inhaled |
| Subject | THC | Unknown | 10 % | Inhaled |